Guatemala

There is no population-wide or systematic dementia screening programme published at the national level. In routine practice, cognitive screening in Guatemala follows regional clinical practice patterns in Latin America, where widely used tools include the Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA). MMSE and its adapted versions have been applied in Guatemalan populations, and both instruments are among the most commonly used cognitive screening tools across the region.

CT and MRI services are available in Guatemala primarily through major public hospitals such as Hospital General San Juan de Dios and Hospital Roosevelt, as well as through the IGSS network, which supplements access through its own facilities and contracted providers. Imaging services, including CT, are documented within these hospitals, although MRI availability is more limited and may involve delays. Advanced imaging capacity, including PET/CT, is concentrated in specialised institutions such as INCAN in Guatemala City and is primarily used for oncology. As a result, access to advanced imaging remains centralised and uneven, shaped by institutional capacity and resource availability.

Genetic testing for Alzheimer’s disease is not part of routine diagnostic practice in Guatemala. As in most Latin American settings, testing is generally limited to rare cases of suspected early-onset familial Alzheimer’s disease involving mutations in APP, PSEN1, or PSEN2. There is no evidence of systematic availability within the public or social security systems, and access is typically restricted to private or research pathways, often requiring out-of-pocket payment and, in some cases, international laboratory processing. Testing for risk alleles such as APOE is not routinely recommended in clinical practice, as it does not provide definitive diagnostic value.

Biomarker-based diagnosis of Alzheimer’s disease is not part of routine clinical practice in Guatemala. While cerebrospinal fluid (CSF) biomarkers and emerging blood-based markers are increasingly used in high-income settings, their availability in Guatemala is extremely limited due to infrastructure, cost, and lack of specialised laboratory capacity. As in other Latin American settings, access to biomarkers is largely restricted to research contexts or highly specialised private services, and most diagnoses rely on clinical assessment supported by basic imaging where available.

Guatemala does not operate a national memory-clinic network, nor does it have a formally articulated dementia service tier within the public health system. Instead, specialised dementia care is concentrated in urban private and academic settings, primarily in Guatemala City. These centres typically provide access to neurology and psychiatry consultations, neuroimaging (CT and MRI), and, where available, neuropsychological assessment. Services are delivered through a mix of private hospitals, specialist offices, and university-affiliated practices, resulting in uneven geographic coverage and limited integration with public primary care.

A central non-state actor is Ermita, which operates a structured dementia day centre in Guatemala City. The centre provides non-pharmacological interventions (cognitive stimulation, occupational and social activities), caregiver respite, and ongoing follow-up for people living with dementia. Ermita also plays a national leadership role in training and capacity building, delivering diploma-level caregiver and professional education in partnership with Galileo University. While Ermita does not substitute for hospital-based diagnostics, it functions as a reference hub for families seeking guidance, continuity, and psychosocial support.

Palliative care services are available mainly within urban hospitals and NGO-supported programmes, often focused on oncology or end-of-life care more broadly. The World Health Organization (WHO) and the International Agency for Research on Cancer (IARC) are working on building palliative care capacities in Guatemala, but mainly for cancer patients. Dementia-specific palliative pathways, addressing advanced cognitive decline, behavioural symptoms, caregiver burden, and ethical decision-making, are not yet systematised in public policy. As a result, late-stage dementia care is typically absorbed into general palliative or family-managed care, with limited specialist input.

The cost of dementia treatment in Guatemala is predominantly out-of-pocket. Medications, follow-up visits, private imaging, and allied services are typically paid directly by families, unless covered through IGSS formularies, private insurance, or specific employer-linked contracts. Even where IGSS coverage exists, access may be constrained by contracted provider networks, geographic proximity, and administrative delays. Given Guatemala’s high out-of-pocket share of total health expenditure, dementia imposes a cumulative financial burden over time—not only through medication costs but also through transport, repeated consultations, and unpaid caregiving labour.

Caregiver support is one of the strongest elements of Guatemala’s dementia ecosystem, though it is driven largely by civil society rather than the state. Ermita provides caregiver education, counselling, peer support groups, and respite care through its day centre. These services help families manage behavioural symptoms, reduce caregiver stress, and maintain care at home for longer periods. At the state level, broader social-protection mechanisms for older persons are gradually evolving. These include a non-contributory cash transfer (Q500 per month) for some adults aged 65 and over, and ongoing work towards a national care system under the leadership of the Ministry of Social Development (MIDES). However, these measures are not dementia-specific, and there is currently no dedicated caregiver allowance, disability benefit, or dementia-linked cash support tied to diagnosis or caregiving intensity.

As a result, while caregiver needs are increasingly recognised in policy discourse, practical support remains fragmented, with NGOs like Ermita filling critical gaps in education, psychosocial assistance, and respite.

Guatemala has not issued a dementia-specific national plan or Alzheimer’s disease strategy. Dementia is not formally defined as a policy priority within the health sector, and there is no publicly articulated framework setting targets for early diagnosis, service development, workforce training, registries, or caregiver support. As a result, dementia is addressed implicitly, through general neurology, psychiatry, ageing, and disability provisions, rather than through a coordinated, condition-specific approach.

The main relevant policy instrument is the National Policy for Comprehensive Care of Older Persons 2018–2032, which establishes broad intersectoral objectives related to healthy ageing, access to health and social services, social inclusion, and protection from abuse and neglect. While this policy creates an enabling umbrella for older-persons care, it does not function as a dementia plan: it lacks operational dementia pathways, financing mechanisms, service standards, or monitoring indicators specific to cognitive impairment. Dementia therefore remains subsumed under general ageing and chronic-care agendas, with limited translation into concrete service expansion or accountability at the system level.

Current government workstreams point to a gradual shift towards a more integrated care agenda, though these initiatives are still under development. Policy discussions led by MIDES reference the construction of a National Social Protection System and a national care framework (Mesa Estratégica de Cuidados) aimed at coordinating responsibilities across health, social development, and labour sectors. These efforts are supported conceptually by international partners, including the United Nations Development Programme (UNDP), and emphasise unpaid care, gender impacts, and population ageing.

If operationalised with strong health–social coordination, these reforms could indirectly benefit dementia care by formalising caregiving roles, improving access to community-based services, and recognising long-term dependency as a policy issue rather than a private family burden. However, dementia is not currently identified as a priority condition within these workstreams.

Innovation in Guatemala’s dementia ecosystem is more visible in service delivery and system organisation than in laboratory or biomarker development. Within the public system, the IGSS has expanded the use of telemedicine and contractual arrangements for advanced imaging (MRI and PET), aiming to improve scheduling flexibility and extend access for insured populations despite limited in-house capacity.

A line of innovation in Guatemala involves a collaborative pilot between a US-based biotech company, Ermita, and Galileo University, focused on the use of voice-based digital biomarkers for earlier detection of dementia. The project applies artificial intelligence and ambient-listening technology to analyse speech patterns associated with cognitive and behavioural change, aiming to identify risk signals before clinical symptoms are clearly manifest. Drawing on real-world patient populations supported by Ermita and academic oversight from Universidad Galileo, the initiative represents a shift toward low-cost, non-invasive screening tools that could be particularly relevant in resource-constrained settings, complementing traditional diagnostics and strengthening early-care planning.